The verdict
Our read at a glance.
Whether teriparatide's approved anabolic osteoporosis benefit is understood within that specific high-fracture-risk setting, rather than generalized.
- The signal
- Randomized trials show teriparatide builds bone density and reduces fractures in osteoporosis. Unlike antiresorptive drugs, it stimulates new bone formation, so it is used in higher-risk patients.
- The unknown
- How best to sequence it with antiresorptive drugs, since bone gains can be lost after stopping, and its long-term positioning against newer anabolic agents.
- Our read
- A proven bone-building osteoporosis drug for high-risk patients. Teriparatide clearly works for its approved use, and the once-feared osteosarcoma signal came from rats and led to a boxed warning that was later removed when human data did not bear it out.
The mechanism
How it works.
Teriparatide is a recombinant copy of the first 34 amino acids of parathyroid hormone, the active end of the molecule. It binds the PTH-1 receptor on bone-building osteoblasts, and because the daily injection delivers the hormone in a brief spike rather than the steady high levels that drive bone loss, that intermittent signal tips the balance toward bone formation. The result is new bone and greater density in people with osteoporosis.
Safety & regulatory boundary
The consequential part.
Teriparatide once carried a boxed warning for a possible osteosarcoma risk based on rat studies, along with a lifetime-use limit. The FDA later removed that boxed warning and the limit after human data did not show the expected risk. It remains a prescription osteoporosis drug for specific high-risk patients. Forteo and other teriparatide products are not the same as compounded or research-labeled teriparatide, and the approved use does not extend to general wellness or anti-aging claims.
What's next
What we're watching.
Sequencing strategies with antiresorptive drugs, long-term safety follow-up, and comparisons with newer anabolic agents.
Context
Why this is discussed.
Teriparatide was the first bone-building osteoporosis drug, a different approach from the more common drugs that slow bone loss.
The evidence base
23 cited references.
Regulatory & labels3
Alvogen, Inc. (FDA label) · 2025
Alvogen Inc. (FDA label) · 2025
BluePoint Laboratories (FDA label) · 2026
Registered trials8
ClinicalTrials.gov · PHASE4 · COMPLETED · 2011-01
ClinicalTrials.gov · RECRUITING · 2025-12-29
ClinicalTrials.gov · NA · ACTIVE_NOT_RECRUITING · 2019-03-01
ClinicalTrials.gov · PHASE1 · RECRUITING · 2026-04-10
ClinicalTrials.gov · PHASE4 · ACTIVE_NOT_RECRUITING · 2022-03-21
ClinicalTrials.gov · PHASE2 · RECRUITING · 2026-04-30
ClinicalTrials.gov · ACTIVE_NOT_RECRUITING · 2008-06
ClinicalTrials.gov · ACTIVE_NOT_RECRUITING · 2004-11
Indexed literature (PubMed)12
Ayers C et al. · Ann Intern Med · 2023
Leder BZ et al. · Lancet · 2015
Nayak S et al. · Osteoporos Int · 2026
Li M et al. · Arch Osteoporos · 2024
Beaudart C et al. · Osteoporos Int · 2025
Anagnostis P et al. · J Clin Endocrinol Metab · 2024
Tsai JN et al. · Lancet · 2013
Beth-Tasdogan NH et al. · Cochrane Database Syst Rev · 2022
Miller PD et al. · JAMA · 2016
Chen L et al. · Front Endocrinol (Lausanne) · 2025
Jin H et al. · Spine J · 2025
Chen T et al. · Biochem Pharmacol · 2021
Keep reading